Structure Therapeutics (NASDAQ:GPCR) Trading Down 5.5% – What’s Next?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares fell 5.5% during mid-day trading on Monday . The company traded as low as $27.29 and last traded at $27.45. 138,739 shares were traded during mid-day trading, a decline of 83% from the average session volume of 796,745 shares. The stock had previously closed at $29.04.

Wall Street Analyst Weigh In

GPCR has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Morgan Stanley assumed coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. JMP Securities reiterated a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, September 23rd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $86.50.

Structure Therapeutics Price Performance

The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -36.65 and a beta of -3.41. The business’s 50-day moving average price is $33.88 and its two-hundred day moving average price is $37.46.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP grew its stake in Structure Therapeutics by 2.9% during the third quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock worth $341,015,000 after buying an additional 221,851 shares in the last quarter. FMR LLC increased its stake in Structure Therapeutics by 6.7% in the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after acquiring an additional 383,635 shares during the last quarter. Janus Henderson Group PLC raised its position in Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after purchasing an additional 602,609 shares in the last quarter. Driehaus Capital Management LLC lifted its stake in Structure Therapeutics by 3.5% during the second quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock worth $101,204,000 after purchasing an additional 86,833 shares during the last quarter. Finally, Federated Hermes Inc. lifted its stake in Structure Therapeutics by 6.6% during the second quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock worth $94,531,000 after purchasing an additional 150,000 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.